Cellectar Biosciences (CLRB) FDA Approvals, PDUFA Dates & Drug Alerts 2026
Decision brief
Answer first · skim in under a minute
Cellectar Biosciences (CLRB) has not received FDA approval in the past two years but has drugs under review, including iopofosine I 131 with Breakthrough Therapy designation. The company is eligible for a Pediatric Review Voucher upon approval, and key PDUFA dates in 2026 will be critical for investors and BD teams.
Cellectar Biosciences has not secured a recent FDA approval for iopofosine I 131, but 2026 company disclosures emphasize Breakthrough Therapy designation in Waldenström macroglobulinemia, confirmatory Phase 3 planning, and a European conditional marketing authorization timeline rather than a posted PDUFA clock.
Contents8 sections
Key Takeaways
- Cellectar reported no FDA product approval for iopofosine I 131 as of its mid-2026 corporate updates.
- FDA has granted Breakthrough Therapy designation for iopofosine I 131 in relapsed/refractory Waldenström macroglobulinemia, plus multiple orphan and Fast Track designations across indications.
- May 2026 updates cite financing of up to $140 million to support a confirmatory study and U.S. accelerated-approval filing plans.
- EMA PRIME designation and a planned EU Conditional Marketing Authorization submission are central 2026 EU catalysts; a specific U.S. PDUFA date was not disclosed in those releases.
Where does iopofosine I 131 stand with FDA in 2026?
Cellectar’s May 14, 2026 Q1 update describes iopofosine I 131 as a phospholipid drug conjugate delivering iodine-131, tested in Phase 2b for relapsed or refractory Waldenström macroglobulinemia (WM), multiple myeloma, and CNS lymphoma.
The company says FDA has granted Breakthrough Therapy designation for r/r WM, along with six Orphan Drug, four Rare Pediatric Drug, and two Fast Track designations across indications, while EMA has granted PRIME designation.
Those designations accelerate interaction and review eligibility. They are not approvals and do not by themselves create a PDUFA goal date.
What 2026 catalysts did Cellectar actually disclose?
Management said it completed financing of up to $140 million to support initiation of a confirmatory study of iopofosine I 131 in r/r WM and a subsequent U.S. FDA filing for accelerated approval.
Positive 12-month follow-up from the Phase 2b CLOVER WaM study was cited as reinforcing confidence to start Phase 3 and file. An SEC Exhibit 99.1 corporate update likewise highlights a Conditional Marketing Authorization path in Europe for potential 2027 EU commercialization timing.
Pediatric high-grade glioma work in CLOVER-2 is the program Cellectar ties to a possible Pediatric Review Voucher if approved — contingent language, not a voucher in hand.
How should investors treat “PDUFA dates & drug alerts 2026” headlines?
Aggregator pages sometimes list Cellectar under FDA event calendars even when no NDA acceptance letter or PDUFA goal date has been published by the company.
As of the May 2026 primary disclosures above, the actionable U.S. milestones are confirmatory trial start and accelerated-approval filing preparation, not a dated FDA action clock.
FDA’s public novel-drug approval trackers on fda.gov novel approvals 2026 remain the place to verify any future approval event if and when it occurs.
For EU teams, CMA submission timing and PRIME interactions are the nearer regulatory workstreams disclosed by the company.
Radiopharmaceutical supply chain, isotope logistics, and site certification often gate commercial readiness even after a positive FDA action. Those operational workstreams deserve equal weight with designation headlines in any 2026 diligence model.
Breakthrough Therapy status can shorten interaction cycles, but accelerated approval still typically requires confirmatory evidence commitments. Missing those commitments later can trigger withdrawal risk — a lesson visible across oncology accelerated approvals in recent FDA practice.
What remains unproven?
CLOVER WaM durability data support the company’s filing narrative but do not guarantee accelerated approval. Confirmatory Phase 3 design agreement with FDA is still a gating execution risk.
Any secondary site that posts a specific 2026 PDUFA date without an FDA or company acceptance disclosure should be treated as unverified.
Pediatric Review Voucher eligibility language is contingent on approval of the pediatric program; it is not a present-day balance-sheet asset.
Sell-side models that insert a 2026 U.S. approval probability without an accepted NDA and PDUFA goal date are mixing designation optimism with calendar fiction. Keep EU CMA and U.S. confirmatory-start milestones on separate lines.
If FDA later posts an acceptance letter, that becomes the moment to add a PDUFA date to coverage — not before. Until then, CLRB remains a clinical and financing execution story centered on iopofosine I 131 in Waldenström macroglobulinemia.
Related NovaPharma coverage
- Cellectar Biosciences company profile
- CHMP May 2026 European drug development
- EU regulatory round-up
Frequently Asked Questions
Has Cellectar received FDA approval for iopofosine I 131?
No. Mid-2026 company updates describe regulatory designations and filing plans, not an approved U.S. marketing authorization for iopofosine I 131.
What FDA designations does iopofosine I 131 hold?
Cellectar says FDA granted Breakthrough Therapy designation in relapsed/refractory Waldenström macroglobulinemia plus multiple Orphan Drug, Rare Pediatric Drug, and Fast Track designations across indications.
Is there a disclosed 2026 PDUFA date for Cellectar?
The company’s May 2026 primary releases emphasize confirmatory study and accelerated-approval filing plans, not a published PDUFA goal date.
Primary Sources
CLRB pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
